US2009275645A1PendingUtilityA1

Method to induce neovascular formation and tissue regeneration

Assignee: STERRENBELD BIOTECHNOLOGIE NORTH AMERICA INCPriority: May 15, 2001Filed: Jun 18, 2009Published: Nov 5, 2009
Est. expiryMay 15, 2021(expired)· nominal 20-yr term from priority
A61K 9/0019A61K 9/127A61K 48/0075A61P 9/10A61K 38/1866A61P 9/00A61K 48/0058
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium.

Claims

exact text as granted — not AI-modified
1 . A method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis in a cell or tissue in need thereof, comprising administering directly to the cell or tissue a dose of a polynucleotide that encodes the vascular endothelial growth factor, VEGF 1-165, or that encodes a polypeptide comprising an active variant of the VEGF 1-165, wherein the coding sequence is operably linked to a CMV promoter and is in a plasmid vector, the dose being in a sufficient amount to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis. 
     
     
         2 . The method of  claim 1 , wherein the VEGF 1-165 has the amino acid sequence: 
       
         
           
                 
               
                   (SEQ ID NO: 1) 
                 
                 
                 
               
                     
                   Ala Pro Met Ala Glu Gly Gly Gly Gln Asn 
                 
                     
                     
                 
                     
                   His His Glu Val Val Lys Phe Met Asp Val 
                 
                     
                     
                 
                     
                   Tyr Gln Arg Ser Tyr Cys His Pro Ile Glu 
                 
                     
                     
                 
                     
                   Thr Leu Val Asp Ile Phe Gln Glu Tyr Pro 
                 
                     
                     
                 
                     
                   Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser 
                 
                     
                     
                 
                     
                   Cys Val Pro Leu Met Arg Cys Gly Gly Cys 
                 
                     
                     
                 
                     
                   Cys Asn Asp Glu Gly Leu Glu Cys Val Pro 
                 
                     
                     
                 
                     
                   Thr Glu Glu Ser Asn Ile Thr Met Gln Ile 
                 
                     
                     
                 
                     
                   Met Arg Ile Lys Pro His Gln Gly Gln His 
                 
                     
                     
                 
                     
                   Ile Gly Glu Met Ser Phe Leu Gln His Asn 
                 
                     
                     
                 
                     
                   Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg 
                 
                     
                     
                 
                     
                   Ala Arg Gln Glu Asn Pro Cys Gly Pro Cys 
                 
                     
                     
                 
                     
                   Ser Glu Arg Arg Lys His Leu Phe Val Gln 
                 
                     
                     
                 
                     
                   Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys 
                 
                     
                     
                 
                     
                   Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln 
                 
                     
                     
                 
                     
                   Leu Glu Leu Asn Glu Arg Thr Cys Arg Cys 
                 
                     
                     
                 
                     
                   Asp Lys Pro Arg Arg. 
                 
             
                
               
            
             
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         3 . The method of  claim 1 , wherein the arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis is induced in vitro or ex vivo. 
     
     
         4 . The method of  claim 1 , wherein the arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis is induced in ischemic tissue, in vitro or ex vivo. 
     
     
         5 . A method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis in a subject in need of such treatment, comprising administering to the subject a dose of a VEGF 1-165 polypeptide, or of an active variant thereof, which is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis.

Join the waitlist — get patent alerts

Track US2009275645A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.